SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: buyhiman who wrote (14226)2/4/1998 2:55:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
As of Monday, the NDA filing for this quarter was "on track". In fact that is the #1 priority and is delaying release of some of the Phase II clinicals, which will likely come next quarter instead of this quarter. I didn't ask about the European filing, but would assume that a US NDA filing will allow for a European filing very soon also.

The clinicals slated for release after the NDA filings are supposed to be robust enough to make believers of anyone who thinks that LGND should be trading at these grossly depressed levels.



To: buyhiman who wrote (14226)2/4/1998 3:00:00 PM
From: Flagrante Delictu  Respond to of 32384
 
buyhiman, As far as we know, LGND is actively pursuing the submission of its NDA on Panretin with a target of getting it done in the first quarter. One would assume that once that was done a European submission would follow. It is remotely possible that both are being worked on simultaneously, although the odds say no. I am sure that Henry will prove a better source on this than I. Regards, Bernie.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News